Skip to main content

Novo Nordisk's diabetes drug Ozempic slashed the risk of kidney disease progression in trial

The results add to the growing evidence that the highly popular injection has broader health benefits for patients beyond treating Type 2 diabetes.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.